Negative regulation of Janus kinases

Cell Biochemistry and Biophysics

Volumn 34, Issue 1, 2001, Pages 17-59

  Duhé, Roy J ^a   Wang, Li Hua ^b   Farrar, William L ^b  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; JAK1 PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; JAK3 PROTEIN, HUMAN; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; ONCOPROTEIN; PROTEIN; PROTEIN TYROSINE KINASE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; CELL TRANSFORMATION; DRUG ANTAGONISM; ENZYME ACTIVATION; ENZYMOLOGY; GENETICS; HUMAN; IMMUNOLOGICAL TOLERANCE; METABOLISM; NEOPLASM; OXIDATION REDUCTION REACTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; ENZYME ACTIVATION; HUMANS; IMMUNE TOLERANCE; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; NEOPLASMS; OXIDATION-REDUCTION; PROTEIN-TYROSINE KINASES; PROTEINS; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 0035234774     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1385/CBB:34:1:17     Document Type: Article

References (212)

1. O'Shea, J. J. (1997) Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet? Immunity. 7, 1-11.
2. Liu, K. D., Gaffen, S. L., and Goldsmith, M. A. (1998) JAK/STAT signaling by cytokine receptors. Curr. Opin. Immunol. 10, 271-278.
3. Duhé, R. J. and Farrar, W. L. (1998) Structural and mechanistic aspects of Janus kinases: How the two-faced god wields a double-edged sword. J. Interferon Cytokine Res. 18, 1-15.
4. Heinrich, P. C., Behrmann, I., Muller-Newen, G., Schaper, F., and Graeve, L. (1998) Interleukin-6-type cytokine signalling through the gp130/ Jak/STAT pathway. Biochem. J. 334, 297-314.
5. Marrero, M. B., Venema, V. J., Ju, H., Eaton, D. C., and Venema, R. C. (1998) Regulation of angiotensin II-induced JAK2 tyrosine phosphorylation: roles of SHP-1 and SHP-2. Am. J. Physiol 275, C1216-C1223.
6. Mellado, M., Rodriguez-Frade, J. M., Aragay, A., del Real, G., Martin, A. M., Vila-Coro, A. J., et al. (1998) The chemokine monocyte chemotactic protein 1 triggers Janus kinase 2 activation and tyrosine phosphorylation of the CCR2B receptor. J. Immunol. 161, 805-813.
7. Rodig, S. J., Meraz, M. A., White, J. M., Lampe, P. A., Riley, J. K., Arthur, C. D., et al. (1998) Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 93, 373-383.
8. Neubauer, H., Cumano, A., Muller, M., Wu, H., Huffstadt, U., and Pfeffer, K. (1998) Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93, 397-409.
9. Parganas, E., Wang, D., Stravopodis, D., Topham, D. J., Marine, J. C., Teglund, S., et al. (1998) Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93, 385-395.
10. Nosaka, T., van Deursen, J. M., Tripp, R. A., Thierfelder, W. E., Witthuhn, B. A., McMickle, A. P., et al. (1995) Defective lymphoid development in mice lacking Jak3. Science 270, 800-802.
11. Park, S. Y., Saijo, K., Takahashi, T., Osawa, M., Arase, H., Hirayama, N., et al. (1995) Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity 3, 771-782.
12. Thomis, D. C., Gurniak, C. B., Tivol, E., Sharpe, A. H., and Berg, L. J. (1995) Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science 270, 794-797.
13. 12a. Karaghiosoff, M., Neubauer, H., Lassnig, C., et al. (2000) Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 13, 549-560.
14. 12b. Shimoda, K., Kato, K., Aoki, K., et al. (2000) Tyk2 plays a restricted role in IFN-α signaling, although it is required for IL-12-mediated T-cell function. Immunity 13, 561-571.
15. Cunningham, B. C., Ultsch, M., de Vos, A. M., Mulkerrin, M. G., Clauser, K. R., and Wells, J. A. (1991) Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science 254, 821-825.
16. De Vos, A. M., Ultsch, M., and Kossiakoff, A. A. (1992) Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255, 306-312.
17. Livnah, O., Stura, E. A., Middleton, S. A., Johnson, D. L., Jolliffe, L. K., and Wilson, I. A. (1999) Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 283, 987-990.
18. Remy, I., Wilson, I. A., and Michnick, S. W. (1999) Erythropoietin receptor activation by a ligand-induced conformation change. Science 283, 990-993.
19. Gauzzi, M. C , Velazquez, L., McKendry, R., Mogensen, K. E., Fellous, M., and Pellegrini, S. (1996) Interferon-alpha-dependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase. J. Biol. Chem. 271, 20,494-20,500.
20. 1007 in the kinase activation loop. Mol. Cell Biol. 17, 2497-2501.
21. Zhou, Y. J., Hanson, E. P., Chen, Y. Q., Magnuson, K., Chen, M., Swann, P. G., et al. (1997) Distinct tyrosine phosphorylation sites in JAK3 kinase domain positively and negatively regulate its enzymatic activity. Proc. Natl. Acad. Sci. USA 94, 13,850-13,855.
22. Zheng, J., Knighton, D. R., Xuong, N. H., Taylor, S. S., Sowadski, J. M., and Ten Eyck, L. F. (1993) Crystal structures of the myristylated catalytic subunit of cAMP-dependent protein kinase reveal open and closed conformation. Protein Sci. 2, 1559-1573.
23. Adams, J. A., McGlone, M. L., Gibson, R., and Taylor, S. S. (1995) Phosphorylation modulates catalytic function and regulation in the cAMP-dependent protein kinase. Biochemistry 34, 2447-2454.
24. Mohammadi, M., Schlessinger, J., and Hubbard, S. R. (1996) Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism. Cell 86, 577-587.
25. Hubbard, S. R. (1997) Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. 16, 5572-5581.
26. Weiss, A. and Schlessinger, J. (1998) Switching signals on or off by receptor dimerization. Cell 94, 277-280.
27. Krishnan, K., Pine, R., and Krolewski, J. J. (1997) Kinase-deficient forms of Jak1 and Tyk2 inhibit interferon alpha signaling in a dominant manner. Eur. J. Biochem. 247, 298-305.
28. Briscoe, J., Rogers, N. C., Witthuhn, B. A., Watling, D., Harpur, A. G., Wilks, A. F., et al. (1996) Kinase-negative mutants of JAK1 can sustain interferon-gamma-inducible gene expression but not an antiviral state. EMBO J. 15, 799-809.
29. Witthuhn, B. A., Williams, M. D., Kerawalla, H., and Uckun, F. M. (1999) Differential substrate recognition capabilities of Janus family protein kinases within the interleukin 2 receptor (IL2R) system: Jak3 as a potential molecular target for treatment of leukemias with a hyperactive Jak-Stat signaling machinery. Leuk. Lymphoma 32, 289-297.
30. Soderling, T. R. (1990) Protein kinases. Regulation by autoinhibitory domains. J. Biol. Chem. 265, 1823-1826.
31. Johnson, L. N., Noble, M. E., and Owen, D. J. (1996) Active and inactive protein kinases: structural basis for regulation. Cell 85, 149-158.
32. Dennis, P. B., Pullen, N., Pearson, R. B., Kozma, S. C., and Thomas, G. (1998) Phosphorylation sites in the autoinhibitory domain participate in p70(s6k) activation loop phosphorylation. J. Biol. Chem. 273, 14,845-14,852.
33. Smith, M. K., Colbran, R. J., Brickey, D. A., and Soderling, T. R. (1992) Functional determinants in the autoinhibitory domain of calcium/calmodulin-dependent protein kinase II. Role of His282 and multiple basic residues. J. Biol. Chem. 267, 1761-1768.
34. Sanchez, V. E. and Carlson, G. M. (1993) Isolation of an autoinhibitory region from the regulatory beta-subunit of phosphorylase kinase. J. Biol. Chem. 268, 17,889-17,895.
35. Goldberg, J., Nairn, A. C., and Kuriyan, J. (1996) Structural basis for the autoinhibition of calcium/calmodulin-dependent protein kinase I. Cell 84, 875-887.
36. Hu, S. H., Lei, J. Y, Wilce, M. C., Valenzuela, M. R., Benian, G. M., Parker, M. W., and Kemp, B. E. (1994) Crystallization and preliminary X-ray analysis of the auto-inhibited twitchin kinase. J. Mol. Biol. 236, 1259-1261.
37. Hu, S. H., Parker, M. W., Lei, J. Y., Wilce, M. C., Benian, G. M., and Kemp, B. E. (1994) Insights into autoregulation from the crystal structure of twitchin kinase. Nature 369, 581-584.
38. Luo, H., Rose, P., Barber, D., Hanratty, W. P., Lee, S., Roberts, T. M., D'Andrea, A. D., and Dearolf, C. R. (1997) Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways. Mol. Cell Biol. 17, 1562-1571.
39. Duhé, R. J. and Farrar, W. L. (1995) Characterization of active and inactive forms of the JAK2 protein-tyrosine kinase produced via the baculovirus expression vector system. J. Biol. Chem. 270, 23,084-23,089.
40. tyk2, an interferon-α inducible tyrosine kinase, suppresses the transformed phenotype of Daudi cells. Leukemia 10, 543-551.
41. Conway, G., Margoliath, A., Wong-Madden, S., Roberts, R. J., and Gilbert, W. (1997) Jak1 kinase is required for cell migrations and anterior specification in zebrafish embryos. Proc. Natl. Acad. Sci. USA 94, 3082-3087.
42. Zhuang, H., Patel, S. V., He, T. C., Niu, Z., and Wojchowski, D. M. (1994) Dominant negative effects of a carboxy-truncated Jak2 mutant on Epo- induced proliferation and Jak2 activation. Biochem. Biophys. Res. Commun. 204, 278-283.
43. Zhuang, H., Patel, S. V., He, T. C., Sonsteby, S. K., Niu, Z., and Wojchowski, D. M. (1994). Inhibition of erythropoietin-induced mitogenesis by a kinase-deficient form of Jak2. J. Biol. Chem. 269, 21,411-21,414.
44. Schindler, C. and Strehlow, I. (2000) Cytokines and STAT signaling. Adv. Pharmacol. 47, 113-74.
45. Chen, X., Vinkemeier, U., Zhao, Y., Jeruzalmi, D., Darnell, J. E., Jr., and Kuriyan, J. (1998) Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell 93, 827-839.
46. Becker, S., Groner, B., and Muller, C. W. (1998) Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature 394, 145-151.
47. Akira, S. (1999) Functional roles of STAT family proteins: lessons from knockout mice. Stem Cells 17, 138-146.
48. Park, C., Li, S., Cha, E., and Schindler, C. (2000) Immune response in Stat2 knockout mice. Immunity, 13, 795-804.
49. Noguchi, M., Yi, H., Rosenblatt, H. M., Filipovich, A. H., Adelstein, S., Modi, W. S., McBride, O. W., and Leonard, W. J. (1993) Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 73, 147-157.
50. Russell, S. M., Tayebi, N., Nakajima, H., Riedy, M. C., Roberts, J. L., Aman, M. J., et al. (1995) Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 270, 797-800.
51. Macchi, P., Villa, A., Giliani, S., Sacco, M. G., Frattini, A., Porta, F., et al. (1995) Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377, 65-68.
52. Cacalano, N. A., Migone, T. S., Bazan, F., Hanson, E. P., Chen, M., Candotti, R, O'Shea, J. J., and Johnston, J. A. (1999) Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain. EMBO J. 18, 1549-1558.
53. Schumacher, R. R, Mella, P., Lalatta, R, Fiorini, M., Giliani, S., Villa, A., Candotti, F., and Notarangelo, L. D. (1999) Prenatal diagnosis of JAK3 deficient SCID. Prenat. Diagn. 19, 653-656.
54. Candotti, F., Oakes, S. A., Johnston, J. A., Notarangelo, L. D., O'Shea, J. J., and Blaese, R. M. (1996) In vitro correction of JAK3-deficient severe combined immunodeficiency by retroviral-mediated gene transduction. J. Exp. Med. 183, 2687-2692.
55. Bunting, K. D., Sangster, M. Y., Ihle, J. N., and Sorrentino, B. P. (1998) Restoration of lymphocyte function in Janus kinase 3-deficient mice by retroviral-mediated gene transfer. Nat. Med. 4, 58-64.
56. Bunting, K. D., Flynn, K. J., Riberdy, J. M., Doherty, P. C., and Sorrentino, B. P. (1999) Virus-specific immunity after gene therapy in a murine model of severe combined immunodeficiency. Proc. Natl. Acad. Sci. USA 96, 232-237.
57. Zhuang, H., Niu, Z., He, T. C., Patel, S. V., and Wojchowski, D. M. (1995) Erythropoietin-dependent inhibition of apoptosis is supported by carboxyl-truncated receptor forms and blocked by dominant-negative forms of Jak2. J. Biol. Chem. 270, 14,500-14,504.
58. Li, S., Labrecque, S., Gauzzi, M. C., Cuddihy, A. R., Wong, A. H., Pellegrini, S., Matlashewski, G. J., and Koromilas, A. E. (1999) The Human papilloma virus (HPV)-IS E6 oncoprotein physically associates with tyk2 and impairs jak-STAT activation by interferon-alpha. Oncogene 18, 5727-5737.
59. Miller, D. M., Rahill, B. M., Boss, J. M., Lairmore, M. D., Durbin, J. E., Waldman, J. W., and Sedmak, D. D. (1998) Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway. J. Exp. Med. 187, 675-683.
60. Lee, E. H. and Rikihisa, Y. (1998) Protein kinase A-mediated inhibition of gamma interferon-induced tyrosine phosphorylation of Janus kinases and latent cytoplasmic transcription factors in human monocytes by Ehrlichia chaffeensis. Infect. Immun. 66, 2514-2520.
61. David, M., Petricoin, E., III, and Larner, A. C. (1996) Activation of protein kinase A inhibits interferon induction of the Jak/Stat pathway in U266 cells. J. Biol. Chem. 271, 4585-4588.
62. Nandan, D. and Reiner, N. E. (1995) Attenuation of gamma interferon-induced tyrosine phosphorylation in mononuclear phagocytes infected with Leishmania donovani: selective inhibition of signaling through Janus kinases and Stat1. Infect. Immun. 63, 4495-4500.
63. Blanchette, J , Racette, N., Faure, R., Siminovitch, K. A., and Olivier, M. (1999) Leishmania-induced increases in activation of macrophage SHP-1 tyrosine phosphatase are associated with impaired IFN-gamma-triggered JAK2 activation. Eur. J. Immunol. 29, 3737-3744.
64. Ben Efraim, S. (1999) One hundred years of cancer immunotherapy: a critical appraisal. Tumor Biol. 20, 1-24.
65. Rosenberg, S. A. (1999) A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10, 281-287.
66. Kolenko, V., Wang, Q., Riedy, M. C., O'Shea, J., Ritz, J., Cathcart, M. K., et al. (1997) Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomas. J. Immunol. 159, 3057-3067.
67. Kolenko, V., Rayman, P., Roy, B., Cathcart, M. K., O'Shea, J., Tubbs, R., et al. (1999) Downregulation of JAK3 protein levels in T lymphocytes by prostaglandin E2 and other cyclic adenosine monophosphate-elevating agents: impact on interleukin-2 receptor signaling pathway. Blood 93, 2308-2318.
68. Meydan, N., Grunberger, T., Dadi, H., Shahar, M., Arpaia, E., Lapidot, Z., et al. (1996) Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379, 645-648.
69. Lacronique, V., Boureux, A., Valle, V. D., Poirel, H., Quang, C. T., Mauchauffe, M., et al. (1997) A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278, 1309-1312.
70. Peeters, P., Raynaud, S. D., Cools, J., Wlodarska, I., Grosgeorge, J., Philip, P., et al. (1997) Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 90, 2535-2540.
71. Ho, J. M., Beattie, B. K., Squire, J. A., Frank, D. A., and Barber, D. L. (1999) Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling. Blood 93, 4354-4364.
72. Schwaller, J., Frantsve, J., Aster, J., Williams, I. R., Tomasson, M. H., Ross, T. S., (1998) Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J. 17, 5321-5333.
73. Zhang, Q., Nowak, I., Vonderheid, E. C., Rook, A. H., Kadin, M. E., Nowell, P. C., Shaw, L. M., and Wasik, M. A. (1996) Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc. Natl. Acad. Sci. USA 93, 9148-9153.
74. Liu, R. Y., Fan, C., Garcia, R., Jove, R., and Zuckerman, K. S. (1999) Constitutive activation of the JAK2/STAT5 signal transduction pathway correlates with growth factor independence of megakaryocytic leukemic cell lines. Blood 93, 2369-2379.
75. Harrison, D. A., Binari, R., Nahreini, T. S., Gilman, M., and Perrimon, N. (1995) Activation of a Drosophila Janus kinase (JAK) causes hematopoietic neoplasia and developmental defects. EMBO J. 14, 2857-2865.
76. Smith, M. R., Duhé, R. J., Liu, Y., and Farrar, W. L. (1997) Microinjected cDNA encoding JAK2 protein-tyrosine kinase induces DNA synthesis in NIH 3T3 cells. FEBS Lett. 408, 327-330.
77. Chaturvedi, P., Reddy, M. V., and Reddy, E. P. (1998) Src kinases and not JAKs activate STATs during IL-3 induced myeloid cell proliferation. Oncogene 16, 1749-1758.
78. Campbell, G. S., Yu, C.-L., Jove, R., and Carter-Su, C. (1997) Constitutive activation of JAK1 in Src-transformed cells. J. Biol. Chem. 272, 2591-2594.
79. Murakami, Y., Nakano, S., Niho, Y., Hamasaki, N., and Izuhara, K. (1998) Constitutive activation of Jak-2 and Tyk-2 in a v-Src-transformed human gallbladder adenocarcinoma cell line. J. Cell Physiol 175, 220-228.
80. Sayeski, P. P., Ali, M. S., Hawks, K., Frank, S. J., and Bernstein, K. E. (1999) The angiotensin II-dependent association of Jak2 and c-Src requires the N-terminus of Jak2 and the SH2 domain of c-Src. Circ. Res. 84, 1332-1338.
81. Yu, C. L., Jove, R., and Burakoff, S. J. (1997) Constitutive activation of the Janus kinase-STAT pathway in T lymphoma overexpressing the Lck protein tyrosine kinase. J. Immunol. 159, 5206-5210.
82. Danial, N. N., Pernis, A., and Rothman, P. B. (1995) Jak-STAT signaling induced by the v-abl oncogene. Science 269, 1875-1877.
83. Shuai, K., Halpern, J., ten Hoeve, J., Rao, X., and Sawyers, C. L. (1996) Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 13, 247-254.
84. Zong, C., Yan, R., August, A., Darnell, J. E., Jr., and Hanafusa, H. (1996) Unique signal transduction of Eyk: constitutive stimulation of the JAK-STAT pathway by an oncogenic receptor-type tyrosine kinase. EMBO J. 15, 4515-4525.
85. Migone, T. S., Lin, J. X., Cereseto, A., Mulloy, J. C., O'Shea, J. J., Franchini, G., and Leonard, W. J. (1995) Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-1. Science 269, 79-81.
86. Xu, X., Kang, S. H., Heidenreich, O., Okerholm, M., O'Shea, J. J., and Nerenberg, M. I. (1995) Constitutive activation of different Jak tyrosine kinases in human T cell leukemia virus type 1 (HTLV-1) tax protein or virus-transformed cells. J. Clin. Invest 96, 1548-1555.
87. Zhang, Q., Lee, B., Korecka, M., Li, G., Weyland, C., Eck, S., et al. (1999) Differences in phosphorylation of the IL-2R associated JAK/STAT proteins between HTLV-I(+), IL-2-independent and IL-2-dependent cell lines and uncultured leukemic cells from patients with adult T-cell lymphoma/leukemia. Leuk. Res. 23, 373-384.
88. Takemoto, S., Mulloy, J. C., Cereseto, A., Migone, T. S., Patel, B. K., Matsuoka, M., et al. (1997) Proliferation of adult T cell leukemia/ lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proc. Natl. Acad. Sci. USA 94, 13,897-13,902.
89. Migone, T. S., Cacalano, N. A., Taylor, N., Yi, T., Waldmann, T. A., and Johnston, J. A. (1998) Recruitment of SH2-containing protein tyrosine phosphatase SHP-1 to the interleukin 2 receptor; loss of SHP-1 expression in human T- lymphotropic virus type I-transformed T cells. Proc. Natl. Acad. Sci. USA 95, 3845-3850.
90. Murata, T. and Puri, R. K. (1997) Comparison of IL-13- and IL-4-induced signaling in EBV-immortalized human B cells. Cell Immunol. 175, 33-40.
91. Gires, O., Kohlhuber, E, Kilger, E., Baumann, M., Kieser, A., Kaiser, C., et al. (1999) Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J. 18, 3064-3073.
92. Lee, Y. H. and Yun, Y. (1998) HBx protein of hepatitis B virus activates Jak1-STAT signaling. J. Biol. Chem. 273, 25,510-25,515.
93. Lamb, P., Haslam, J., Kessler, L., Seidel, H. M., Stein, R. B., and Rosen, J. (1994) Rapid activation of the interferon-gamma signal transduction pathway by inhibitors of tyrosine phosphatases. J. Interferon Res. 14, 365-373.
94. Haque, S. J., Wu, Q., Kammer, W., Friedrich, K., Smith, J. M., Kerr, I. M., Stark, G. R., and Williams, B. R. (1997) Receptor-associated constitutive protein tyrosine phosphatase activity controls the kinase function of JAK1. Proc. Natl. Acad. Sci. USA 94, 8563-8568.
95. Klingmüller, U., Lorenz, U., Cantley, L. C., Neel, B. G., and Lodish, H. F. (1995) Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 80, 729-738.
96. Jiao, H., Berrada, K., Yang, W., Tabrizi, M., Platanias, L. C., and Yi, T. (1996) Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1. Mol. Cell Biol. 16, 6985-6992.
97. Stahl, N., Farruggella, T. J., Boulton, T. G., Zhong, Z., Darnell, J. E., Jr., and Yancopoulos, G. D. (1995) Choice of STATs and other substrates specified by modular tyrosine- based motifs in cytokine receptors. Science 267, 1349-1353.
98. Yetter, A., Uddin, S., Krolewski, J. J., Jiao, H., Yi, T., and Platanias, L. C. (1995) Association of the interferon-dependent tyrosine kinase Tyk-2 with the hematopoietic cell phosphatase. J. Biol. Chem. 270, 18,179-18,182.
99. David, M., Chen, H. E., Goelz, S., Larner, A. C., and Neel, B. G. (1995) Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol. Cell Biol. 15, 7050-7058.
100. Haque, S. J., Harbor, P., Tabrizi, M., Yi, T., and Williams, B. R. (1998) Protein-tyrosine phosphatase Shp-1 is a negative regulator of IL-4-and IL-13-dependent signal transduction. J. Biol. Chem. 273, 33,893-33,896.
101. Tabrizi, M., Yang, W., Jiao, H., DeVries, E. M., Platanias, L. C., Arico, M., and Yi, T. (1998) Reduced Tyk2/SHP-1 interaction and lack of SHP-1 mutation in a kindred of familial hemophagocytic lymphohistiocytosis. Leukemia 12, 203-206.
102. Ram, P. A. and Waxman, D. J. (1997) Interaction of growth hormone-activated STATs with SH2-containing phosphotyrosine phosphatase SHP-1 and nuclear JAK2 tyrosine kinase. J. Biol. Chem. 272, 17,694-17,702.
103. Lobie, P. E., Ronsin, B., Silvennoinen, O., Haldosen, L. A., Norstedt, G., and Morel, G. (1996) Constitutive nuclear localization of Janus kinases 1 and 2. Endocrinology 137, 4037-4045.
104. Bousquet, C., Susini, C., and Melmed, S. (1999) Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor. J. Clin. Invest 104, 1277-1285.
105. Tidow, N., Kasper, B., and Welte, K. (1999) SH2-containing protein tyrosine phosphatases SHP-1 and SHP-2 are dramatically increased at the protein level in neutrophils from patients with severe congenital neutropenia (Kostmann's syndrome). Exp. Hematol. 27, 1038-1045.
106. Raupich, P., Kasper, B., Tidow, N., and Welte, K. (1995) The protein tyrosine kinase JAK2 is activated in neutrophils from patients with severe congenital neutropenia. Blood 86, 4500-4505.
107. Berchtold, S , Volarevic, S., Moriggl, R., Mercep, M., and Groner, B. (1998) Dominant negative variants of the SHP-2 tyrosine phosphatase inhibit prolactin activation of Jak2 (janus kinase 2) and induction of Stat5 (signal transducer and activator of transcription 5)-dependent transcription. Mol. Endocrinol. 12, 556-567.
108. Gadina, M., Stancato, L. M., Bacon, C. M., Larner, A. C., and O'Shea, J. J. (1998) Involvement of SHP-2 in multiple aspects of IL-2 signaling: evidence for a positive regulatory role. J. Immunol 160, 4657-4661.
109. Maegawa, H., Kashiwagi, A., Fujita, T., Ugi, S., Hasegawa, M., Obata, T., et al. (1996) SHPTP2 serves adapter protein linking between Janus kinase 2 and insulin receptor substrates. Biochem. Biophys. Res. Commun. 228, 122-127.
110. Yin, T., Shen, R., Feng, G. S., and Yang, Y. C. (1997) Molecular characterization of specific-interactions between SHP-2 phosphatase and JAK tyrosine kinases. J. Biol. Chem. 272, 1032-1037.
111. You, M., Yu, D. H., and Feng, G. S. (1999) Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol. Cell Biol. 19, 2416-2424.
112. Li, C. and Friedman, J. M. (1999) Leptin receptor activation of SH2 domain containing protein tyrosine phosphatase 2 modulates Ob receptor signal transduction. Proc. Natl. Acad. Sci. USA 96, 9677-9682.
113. Nicholson, S. E. and Hilton, D. J. (1998) The SOCS proteins: a new family of negative regulators of signal transduction. J. Leukoc. Biol. 63, 665-668.
114. Starr, R. and Hilton, D. J. (1998) SOCS: suppressors of cytokine signalling. Int. J. Biochem. Cell Biol. 30, 1081-1085.
115. Alexander, W. S., Starr, R., Metcalf, D., Nicholson, S. E., Farley, A., Elefanty, A. G., et al. (1999) Suppressors of cytokine signaling (SOCS): negative regulators of signal transduction. J. Leukoc. Biol. 66, 588-592.
116. Metcalf, D. (1999) The SOCS-1 story. Exp. Hematol. 27, 1715-1723.
117. Gisselbrecht, S. (1999) The CIS/SOCS proteins: a family of cytokine-inducible regulators of signaling. Eur. Cytokine Netw. 10, 463-470.
118. Yoshimura, A., Ohkubo, T., Kiguchi, T., Jenkins, N. A., Gilbert, D. J., Copeland, N. G., Hara, T., and Miyajima, A. (1995) A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J. 14, 2816-2826.
119. Matsumoto, A., Masuhara, M., Mitsui, K., Yokouchi, M., Ohtsubo, M., Misawa, H., Miyajima, A., and Yoshimura, A. (1997) CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood 89, 3148-3154.
120. Endo, T. A., Masuhara, M., Yokouchi, M., Suzuki, R., Sakamoto, H., Mitsui, K., et al. (1997) A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387, 921-924.
121. Naka, T., Narazaki, M., Hirata, M., Matsumoto, T., Minamoto, S., Aono, A., et al. (1997) Structure and function of a new STAT-induced STAT inhibitor. Nature 387, 924-929.
122. Starr, R., Willson, T. A., Viney, E. M., Murray, L. J., Rayner, J. R., Jenkins, B. J., et al. (1997) A family of cytokine-inducible inhibitors of signalling. Nature 387, 917-921.
123. Masuhara, M., Sakamoto, H., Matsumoto, A., Suzuki, R., Yasukawa, H., Mitsui, K., et al. (1997) Cloning and characterization of novel CIS family genes. Biochem. Biophys. Res. Commun. 239, 439-446.
124. Minamoto, S., Ikegame, K., Ueno, K., Narazaki, M., Naka, T., Yamamoto, H., et al. (1997) Cloning and functional analysis of new members of STAT induced STAT inhibitor (SSI) family: SSI-2 and SSI-3. Biochem. Biophys. Res. Commun. 237, 79-83.
125. Hilton, D. J., Richardson, R. T., Alexander, W. S., Viney, E. M., Willson, T. A., Sprigg, N. S., et al. (1998) Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc. Natl. Acad. Sci. USA 95, 114-119.
126. Starr, R., Metcalf, D., Elefanty, A. G., Brysha, M., Willson, T. A., Nicola, N. A., Hilton, D. J., and Alexander, W. S. (1998) Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proc. Natl. Acad. Sci. USA 95, 14,395-14,399.
127. Naka, T., Matsumoto, T., Narazaki, M., Fujimoto, M., Morita, Y., Ohsawa, Y., et al. (1998) Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT inhibitor-1) deficient mice. Proc. Natl. Acad. Sci. USA 95, 15,577-15,582.
128. Alexander, W. S., Starr, R., Fenner, J. E., Scott, C. L., Handman, E., Sprigg, N. S., et al. (1999) SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 98, 597-608.
129. Marine, J. C., Topham, D. J., McKay, C., Wang, D., Parganas, E., Stravopodis, D., Yoshimura, A., and Ihle, J. N. (1999) SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell 98, 609-616.
130. Young, H. A., Klinman, D. M., Reynolds, D. A., Grzegorzewski, K. J., Nii, A., Ward, J. M., et al. (1997) Bone marrow and thymus expression of interferon-gamma results in severe B-cell lineage reduction, T-cell lineage alterations, and hematopoietic progenitor deficiencies. Blood 89, 583-595.
131. Yasukawa, H., Misawa, H., Sakamoto, H., Masuhara, M., Sasaki, A., Wakioka, T., et al. (1999) The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 18, 1309-1320.
132. Narazaki, M., Fujimoto, M., Matsumoto, T., Morita, Y., Saito, H., Kajita, T., et al. (1998) Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling. Proc. Natl. Acad. Sci. USA 95, 13,130-13,134.
133. Nicholson, S. E., Willson, T. A., Farley, A., Starr, R., Zhang, J. G., Baca, M., et al. (1999) Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J. 18, 375-385.
134. Ohya, K., Kajigaya, S., Yamashita, Y., Miyazato, A., Hatake, K., Miura, Y., et al. (1997) SOCS-1/JAB/SSI-1 can bind to and suppress Tec protein-tyrosine kinase. J. Biol. Chem. 272, 27,178-27,182.
135. De Sepulveda, P., Okkenhaug, K., Rose, J. L., Hawley, R. G., Dubreuil, P., and Rottapel, R. (1999) Socs1 binds to multiple signalling proteins and suppresses steel factor-dependent proliferation. EMBO J. 18, 904-915.
136. Sakamoto, H., Yasukawa, H., Masuhara, M., Tanimura, S., Sasaki, A., Yuge, K., et al. (1998) A janus kinase inhibitor, JAB, is an interferon-γ-inducible gene and confers resistance to interferons. Blood 92, 1668-1676.
137. Dickensheets, H. L. and Donnelly, R. P. (1999) Inhibition of IL-4-inducible gene expression in human monocytes by type I and type II interferons. J. Leukoc. Biol. 65, 307-312.
138. Losman, J. A., Chen, X. P., Hilton, D., and Rothman, P. (1999) SOCS-1 is a potent inhibitor of IL-4 signal transduction. J. Immunol. 162, 3770-3774.
139. Venkataraman, C., Leung, S., Salvekar, A., Mano, H., and Schindler, U. (1999) Repression of IL-4-induced gene expression by IFN-gamma requires Stat1 activation. J. Immunol. 162, 4053-4061.
140. Dickensheets, H. L., Venkataraman, C., Schindler, U., and Donnelly, R. P. (1999) Interferons inhibit activation of STAT6 by interleukin 4 in human monocytes by inducing SOCS-1 gene expression. Proc. Natl Acad. Sci. USA 96, 10,800-10,805.
141. Bjørbaek, C., Elmquist, J. K., Frantz, J. D., Shoelson, S. E., and Flier, J. S. (1998) Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol. Cell 1, 619-625.
142. Emilsson, V., Arch, J. R., de Groot, R. P., Lister, C. A., and Cawthorne, M. A. (1999) Leptin treatment increases suppressors of cytokine signaling in central and peripheral tissues. FEBS Lett. 455, 170-174.
143. Bjørbaek, C., EI Haschimi, K., Frantz, J. D., and Flier, J. S. (1999) The role of SOCS-3 in leptin signaling and leptin resistance. J. Biol. Chem. 274, 30,059-30,065.
144. Bjørbaek, C., Elmquist, J. K., EI Haschimi, K., Kelly, J., Ahima, R. S., Hileman, S., and Flier, J. S. (1999) Activation of SOCS-3 messenger ribonucleic acid in the hypothalamus by ciliary neurotrophic factor. Endocrinology 140, 2035-2043.
145. Auernhammer, C. J., Chesnokova, V., Bousquet, C., and Melmed, S. (1998) Pituitary corticotroph SOCS-3: novel intracellular regulation of leukemia-inhibitory factor-mediated proopiomelanocortin gene expression and adrenocorticotropin secretion. Mol. Endocrinol. 12, 954-961.
146. Auernhammer, C. J. and Melmed, S. (1999) Interleukin-11 stimulates proopiomelanocortin gene expression and adrenocorticotropin secretion in corticotroph cells: evidence for a redundant cytokine network in the hypothalamo-pituitary-adrenal axis. Endocrinology 140, 1559-1566.
147. Adams, T. E., Hansen, J. A., Starr, R., Nicola, N. A., Hilton, D. J., and Billestrup, N. (1998) Growth hormone preferentially induces the rapid, transient expression of SOCS-3, a novel inhibitor of cytokine receptor signaling. J. Biol. Chem. 273, 1285-1287.
148. Ram, P. A. and Waxman, D. J. (1999) SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. J. Biol. Chem. 274, 35,553-35,561.
149. Favre, H., Benhamou, A., Finidori, J., Kelly, P. A., and Edery, M. (1999) Dual effects of suppressor of cytokine signaling (SOCS-2) on growth hormone signal transduction. FEBS Lett. 453, 63-66.
150. Stoiber, D., Kovarik, P., Cohney, S., Johnston, J. A., Steinlein, P., and Decker, T. (1999) Lipopolysaccharide induces in macrophages the synthesis of the suppressor of cytokine signaling 3 and suppresses signal transduction in response to the activating factor IFN-gamma. J. Immunol. 163, 2640-2647.
151. Ito, S., Ansari, P., Sakatsume, M., Dickensheets, H., Vazquez, N., Donnelly, R. P., Larner, A. C., and Finbloom, D. S. (1999) Interleukin-10 inhibits expression of both interferon α and interferon-γ-induced genes by supressing tyrosine phosphorylation of STAT1. Blood 93, 1456-1463.
152. Cassatella, M. A., Gasperini, S., Bovolenta, C., Calzetti, F., Vollebregt, M., Scapini, P., et al. (1999) Interleukin-10 (IL-10) selectively enhances CIS3/SOCS3 mRNA expression in human neutrophils: evidence for an IL-10-induced pathway that is independent of STAT protein activation. Blood 94, 2880-2889.
153. Cohney, S. J., Sanden, D., Cacalano, N. A., Yoshimura, A., Mui, A., Migone, T. S., and Johnston, J. A. (1999) SOCS-3 is tyrosine phosphorylated in response to interleukin-2 and suppresses STAT5 phosphorylation and lymphocyte proliferation. Mol. Cell Biol. 19, 4980-4988.
154. Marine, J. C., McKay, C., Wang, D., Topham, D. J., Parganas, E.,
155. Dey, B. R., Spence, S. L., Nissley, P., and Furlanetto, R. W. (1998) Interaction of human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-I receptor. J. Biol. Chem. 273, 24,095-24,101.
156. Song, M. M. and Shuai, K. (1998) The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J. Biol. Chem. 273, 35,056-35,062.
157. Yu, C. L. and Burakoff, S. J. (1997) Involvement of proteasomes in regulating Jak-STAT pathways upon interleukin-2 stimulation. J. Biol. Chem. 272, 14,017-14,020.
158. Gebert, C. A., Park, S. H., and Waxman, D. J. (1999) Down-regulation of liver JAK2-STAT5b signaling by the female plasma pattern of continuous growth hormone stimulation. Mol. Endocrinol. 13, 213-227.
159. Gebert, C. A., Park, S. H., and Waxman, D. J. (1999) Termination of growth hormone pulse-induced STAT5b signaling. Mol. Endocrinol. 13, 38-56.
160. Callus, B. A. and Mathey-Prevot, B. (1998) Interleukin-3-induced activation of the JAK/STAT pathway is prolonged by proteasome inhibitors. Blood 91, 3182-3192.
161. Verdier, F. Chrétien, S., Muller, O., Vrlet, P., Yoshimura, A., Gisselbrecht, S., Lacombe, C., and Mayeux, P. (1998) Proteasomes regulate erythropoietin receptor and signal transducer and activator of transcription 5 (STAT5) activation. J. Biol. Chem. 273, 28,185-28,190.
162. Kamura, T., Sato, S., Haque, D., Liu, L., Kaelin, W. G., Jr., Conaway, R. C., and Conaway, J. W. (1998) The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev. 12, 3872-3881.
163. Zhang, J. -G., Farley, A., Nicholson, S. E., Willson, T. A., Zugaro, L. M., Simpson, R. J., et al. (1999) The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc. Natl. Acad. Sci. USA 96, 2071-2076.
164. Yokouchi, M., Suzuki, R., Masuhara, M., Komiya, S., Inoue, A., and Yoshimura, A. (1997) Cloning and characterization of APS, an adaptor molecule containing PH and SH2 domains that is tyrosine phosporylated upon B cell receptor stimulation. Oncogene 15, 7-15.
165. Wakioka, T., Sasaki, A., Mitsui, K., Yokouchi, M., Inoue, A., Komiya, S., and Yoshimura, A. (1999) APS, an adaptor protein containing Pleckstrin homology (PH) and Src homology-2 (SH2) domains inhibits the JAK-STAT pathway in collaboration with c-Cbl. Leukemia 13, 760-767.
166. Rui, L., Mathews, L. S., Hotta, K., Gustafson, T. A., and Carter-Su, C. (1997) Identification of SH2-Bβ as a substrate of the tyrosine kinase JAK2 involved in growth hormone signaling. Mol. Cell. Biol. 17, 6633-6644.
167. Rui, L. and Carter-Su, C. (1999) Identification of SH2-Bβ as a potent cytoplasmic activator of the tyrosine kinase Janus kinase 2. Proc. Natl. Acad. Sci. USA 96, 7172-7177.
168. Bright, J. J., Kerr, L. D., and Sriram, S. (1997) TGF-beta inhibits IL-2-induced tyrosine phosphorylation and activation of Jak-1 and Stat 5 in T lymphocytes. J. Immunol. 159, 175-183.
169. Bright, J. J. and Sriram, S. (1998) TGF-beta inhibits IL-12-induced activation of Jak-STAT pathway in T lymphocytes. J. Immunol. 161, 1772-1777.
170. Sudarshan, C., Galon, J., Zhou, Y., and O'Shea, J. J. (1999) TGF-beta does not inhibit IL-12-and IL-2-induced activation of Janus kinases and STATs. J. Immunol. 162, 2974-2981.
171. Han, H. S., Jun, H. S., Utsugi, T., and Yoon, J. W. (1997) Molecular role of TGF-beta, secreted from a new type of CD4+ suppressor T cell, NY4.2, in the prevention of autoimmune IDDM in NOD mice. J. Autoimmun. 10, 299-307.
172. Pardoux, C., Ma, X., Gobert, S., Pellegrini, S., Mayeux, P., Gay, F., Trinchieri, G., and Chouaib, S. (1999) Downregulation of interleukin-12 (IL-12) responsiveness in human T cells by transforming growth factor-beta: relationship with IL-12 signaling. Blood 93, 1448-1455.
173. Pazdrak, K., Justement, L., and Alam, R. (1995) Mechanism of inhibition of eosinophil activation by transforming growth factor-beta. Inhibition of Lyn, MAP, Jak2 kinases and STAT1 nuclear factor. J. Immunol. 155, 4454-4458.
174. Nandan, D. and Reiner, N. E. (1997) TGF-beta attenuates the class II transactivator and reveals an accessory pathway of IFN-gamma action. J. Immunol. 158, 1095-1101.
175. Panek, R. B., Lee, Y. J., and Benveniste, E. N. (1995) TGF-beta suppression of IFN-gamma-induced class II MHC gene expression does not involve inhibition of phosphorylation of JAK1, JAK2, or signal transducers and activators of transcription, or modification of IFN-gamma enhanced factor X expression. J. Immunol. 154, 610-619.
176. Duhé, R. J., Evans, G. A., Erwin, R. A., Kirken, R. A., Cox, G. W., and Farrar, W. L. (1998) Nitric oxide and thiol redox regulation of Janus kinase activity. Proc. Natl. Acad. Sci. USA 95, 126-131.
177. Bingisser, R. M., Tilbrook, P. A., Holt, P. G., and Kees, U. R. (1998) Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J. Immunol. 160, 5729-5734.
178. Mills, C. D. (1991) Molecular basis of "suppressor" macrophages. Arginine metabolism via the nitric oxide synthetase pathway. J. Immunol. 146, 2719-2723.
179. Albina, J. E., Abate, J. A., and Henry, W. L., Jr. (1991) Nitric oxide production is required for murine resident peritoneal macrophages to suppress mitogen-stimulated T cell proliferation. Role of IFN-gamma in the induction of the nitric oxide-synthesizing pathway. J. Immunol. 147, 144-148.
180. Taylor-Robinson, A. W., Liew, F. Y., Severn, A., Xu, D., McSorley, S. J., Garside, P., Padron, J., and Phillips, R. S. (1994) Regulation of the immune response by nitric oxide differentially produced by T helper type 1 and T helper type 2 cells. Eur. J. Immunol. 24, 980-984.
181. Lejeune, P., Lagadec, P., Onier, N., Pinard, D., Ohshima, H., and Jeannin, J. F. (1994) Nitric oxide involvement in tumor-induced immunosuppression. J. Immunol. 152, 5077-5083.
182. Yamauchi, A., Masutani, H., Tagaya, Y., Wakasugi, N., Mitsui, A., Nakamura, H., et al. (1992) Lymphocyte transformation and thiol compounds: the role of ADF/thioredoxin as an endogenous reducing agent. Mol. Immunol. 29, 263-270.
183. Iwata, S., Hori, T., Sato, N., Ueda-Taniguchi, Y., Yamabe, T., Nakamura, H., Masutani, H., and Yodoi, J. (1994) Thiol-mediated redox regulation of lymphocyte proliferation. Possible involvement of adult T cell leukemia-derived factor and glutathione in transferrin receptor expression. J. Immunol. 152, 5633-5642.
184. Yamauchi, A. and Bloom, E. T. (1993) Requirement of thiol compounds as reducing agents for IL-2-mediated induction of LAK activity and proliferation of human NK cells. J. Immunol. 151, 5535-5544.
185. Carballo, M., Conde, M., El Bekay, R., Martin-Nieto, J., Camacho, M. J., Monteseirin, J., et al. (1999) Oxidative stress triggers STAT3 tyrosine phosphorylation and nuclear translocation in human lymphocytes. J. Biol. Chem. 274, 17,580-17,586.
186. Simon, A. R., Rai, U., Fanburg, B. L., and Cochran, B. H. (1998) Activation of the JAK-STAT pathway by reactive oxygen species. Am. J. Physiol 275, C1640-C1652.
187. Fauman, E. B. and Saper, M. A. (1996) Structure and function of the protein tyrosine phosphatases. Trends Biochem. Sci. 21, 413-417.
188. Pannifer, A. D., Flint, A. J., Tonks, N. K., and Barford, D. (1998) Visualization of the cysteinyl-phosphate intermediate of a protein-tyrosine phosphatase by x-ray crystallography. J. Biol. Chem. 273, 10,454-10,462.
189. Abe, J. and Berk, B. C. (1999) Fyn and JAK2 mediate Ras activation by reactive oxygen species. J. Biol. Chem. 274, 21,003-21,010.
190. Radi, R., Beckman, J. S., Bush, K. M., and Freeman, B. A. (1991) Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. J. Biol. Chem. 266, 4244-4250.
191. Levitzki, A. and Gazit, A. (1995) Tyrosine kinase inhibition: an approach to drug development. Science 267, 1782-1788.
192. Lawrence, D. S. and Niu, J. (1998) Protein kinase inhibitors: the tyrosine-specific protein kinases. Pharmacol. Ther. 77, 81-114.
193. Fiorucci, G., Percario, Z. A., Marcolin, C., Coccia, E. M., Affabris, E., and Romeo, G. (1995) Inhibition of protein phosphorylation modulates expression of the Jak family protein tyrosine kinases. J. Virol. 69, 5833-5837.
194. Elder, R. T., Xu, X., Williams, J. W., Gong, H., Finnegan, A., and Chong, A. S. (1997) The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J. Immunol. 159, 22-27.
195. Siemasko, K., Chong, A. S., Jack, H. M., Gong, H., Williams, J. W., and Finnegan, A. (1998) Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J. Immunol. 160, 1581-1588.
196. Wasik, M. A., Nowak, I., Zhang, Q., and Shaw, L. M. (1998) Suppression of proliferation and phosphorylation of Jak3 and STAT5 in malignant T-cell lymphoma cells by derivatives of octylamino-undecyl-dimethylxanthine. Leuk. Lymphoma 28, 551-560.
197. Osherov, N., Gazit, A., Gilon, C., and Levitzki, A. (1993) Selective inhibition of the epidermal growth factor and HER2/neu receptors by tyrphostins. J. Biol. Chem. 268, 11,134-11,142.
198. Sharfe, N., Dadi, H. K., and Roifman, C. M. (1995) JAK3 protein tyrosine kinase mediates interleukin-7-induced activation of phosphatidylinositol-3′ kinase. Blood 86, 2077-2085.
199. 1 receptor in response to angiotensin II. Biochem. Biophys. Res. Commun. 249, 672-677.
200. Miike, S., Nakao, A., Hiraguri, M., Kurasawa, K., Saito, Y., and Iwamoto, I. (1999) Involvement of JAK2, but not PI 3-kinase/Akt and MAP kinase pathways, in anti-apoptotic signals of GM-CSF in human eosinophils. J. Leukoc. Biol. 65, 700-706.
201. Simon, H. -U., Yousefi, S., Dibbert, B., LeviSchaffer, F., and Blaser, K. (1997) Anti-apoptotic signals of granulocyte-macrophage colony-stimulating factor are transduced via Jak2 tyrosine kinase in eosinophils. Eur. J. Immunol. 27, 3536-3539.
202. Kirken, R. A., Erwin, R. A., Taub, D., Murphy, W. J., Behbod, F., Wang, L., Pericle, F., and Farrar, W. L. (1999) Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells. J. Leukoc. Biol. 65, 891-899.
203. Wang, L. H., Kirken, R. A., Erwin, R. A., Yu, C. R., and Farrar, W. L. (1999) JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response. J. Immunol. 162, 3897-3904.
204. Bright, J. J., Du, C., and Sriram, S. (1999) Tyrphostin B42 inhibits IL-12-induced tyrosine phosphorylation and activation of Janus kinase-2 and prevents experimental allergic encephalomyelitis. J. Immunol. 162, 6255-6262.
205. Nielsen, M., Kaltoft, K., Nordahl, M., Röpke, C., Geisler, C., Mustelin, T., et al. (1997) Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoldes: Tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc. Natl. Acad. Sci. USA 94, 6764-6769.
206. Constantin, G., Brocke, S., Izikson, A., Laudanna, C., and Butcher, E. C. (1998) Tyrphostin AG490, a tyrosine kinase inhibitor, blocks actively induced experimental autoimmune encephalomyelitis. Eur. J. Immunol. 28, 3523-3529.
207. Constantin, G., Laudanna, C., Brocke, S., and Butcher, E. C. (1999) Inhibition of experimental autoimmune encephalomyelitis by a tyrosine kinase inhibitor. J. Immunol. 162, 1144-1149.
208. Goodman, P. A., Niehoff, L. B., and Uckun, F. M. (1998) Role of tyrosine kinases in induction of the c-jun proto-oncogene in irradiated B-lineage lymphoid cells. J. Biol. Chem. 273, 17742-17748.
209. Sudbeck, E. A., Liu, X. P., Narla, R. K., Mahajan, S., Ghosh, S., Mao, C., and Uckun, F. M. (1999) Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin. Cancer Res. 5, 1569-1582.
210. Uckun, F. M., Ek, O., Liu, X. P., and Chen, C. L. (1999) In vivo toxicity and pharmacokinetic features of the janus kinase 3 inhibitor WHI-P131 [4-(4′hydroxyphenyl)-amino-6,7-dimethoxyquinazoline. Clin. Cancer Res. 5, 2954-2962.
211. Malaviya, R. and Uckun, F. M. (1999) Genetic and biochemical evidence for a critical role of Janus kinase (JAK)-3 in mast cell-mediated type I hypersensitivity reactions. Biochem. Biophys. Res. Commun. 257, 807-813.
212. Malaviya, R., Zhu, D., Dibirdik, I., and Uckun, F. M. (1999) Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis. J. Biol. Chem. 274, 27,028-27,038.